Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Medical Genetics · Glycogen Storage Disease Type III

Building Your Care Team and Lifelong Surveillance

At a Glance

Glycogen Storage Disease Type III (GSD III) requires lifelong management by a multidisciplinary team, including a metabolic geneticist, dietitian, hepatologist, and cardiologist. Regular surveillance of the liver, heart, and muscles through imaging and blood tests is critical to detect and prevent long-term complications.

Because Glycogen Storage Disease Type III (GSD III) is a multisystem condition, management requires a “village” of specialists [1][2]. While the early years often focus on the liver and blood sugar, lifelong health depends on systematic monitoring of the heart and muscles as well [3][4].

Your Multidisciplinary Team

A coordinated approach is the most effective way to address the complexities of GSD III [3]. Your core team should ideally include:

  • Metabolic Geneticist: Leads the overall treatment plan and explains genetic risks [5].
  • Specialized Metabolic Dietitian: The most critical member for daily management, helping you fine-tune protein intake and cornstarch doses [6].
  • Hepatologist (Liver Specialist): Monitors for liver scarring (fibrosis) and potential growths [7][8].
  • Cardiologist: Performs regular checks on heart muscle thickness and function [9].
  • Neurologist/Physical Therapist: Tracks muscle strength and monitors for signs of myopathy (muscle disease) [10][11].

The Surveillance Roadmap

Monitoring in GSD III is about catching “silent” changes before they cause symptoms. While schedules are personalized, typical surveillance intervals include:

Organ System Key Risks Recommended Tests Frequency (Typical)
Liver Fibrosis, Cirrhosis, Adenomas, and HCC (Liver Cancer) [7][12] Ultrasound or MRI; Liver Enzymes (AST/ALT) [1] Yearly for children; every 6–12 months for adults [7].
Heart Cardiomyopathy (Thickening of the heart muscle) [9] Echocardiogram; EKG [13] Every 1–2 years, or more frequently if changes are noted [9].
Muscles Progressive Weakness and Myopathy [10] Physical exam; Creatine Kinase (CK) levels [14] Every 6–12 months [1].

Understanding Your Biomarkers

Your care team will use specific “clues” in your blood to see how well the disease is being managed:

  • AST and ALT: These liver enzymes indicate how much stress or damage the liver is experiencing. High levels can suggest the liver is working too hard to handle stored glycogen [8][15].
  • Creatine Kinase (CK): This is the primary marker for muscle health. Elevated CK levels often mean that muscle cells are leaking energy, which can be a sign that the muscles need more protein for fuel [14][16].
  • Urinary Glc4: This specialized marker tracks the overall “turnover” of glycogen in the body. While it can vary based on diet, it helps doctors see if glycogen buildup is stable or increasing [17].

Long-Term Risks to Keep in Mind

While GSD III is manageable, staying vigilant about three primary long-term risks is essential for a healthy future:

  1. Liver Growths: Patients with GSD III can develop liver tumors (adenomas), and in some cases, these can lead to Hepatocellular Carcinoma (HCC), even if the liver doesn’t show signs of cirrhosis [12][12].
  2. Muscle Progression: In Type IIIa, muscle weakness can become more prominent in the 30s and 40s. Proactive physical therapy and high-protein nutrition are key tools to delay this [10][18].
  3. Cardiac Thickening: Glycogen buildup can cause the heart walls to thicken (hypertrophy). Specialized diets (like the modified Atkins diet) are now being used to help reverse these heart changes [13][9].

Common questions in this guide

Which specialists do I need on my GSD III care team?
A comprehensive care team for GSD III should include a metabolic geneticist, a specialized metabolic dietitian, a hepatologist to monitor liver health, a cardiologist, and a neurologist or physical therapist. This multidisciplinary approach ensures all affected body systems are properly managed.
How often should I have liver imaging for GSD III?
Liver monitoring typically involves an ultrasound or MRI, which is recommended yearly for children and every 6 to 12 months for adults. This frequent surveillance helps detect early signs of fibrosis, cirrhosis, or liver growths before they cause symptoms.
What does an elevated Creatine Kinase (CK) level mean?
Creatine Kinase is a key blood marker used to evaluate muscle health. Elevated CK levels often indicate that muscle cells are leaking energy, which can be a sign of muscle stress and may suggest your body needs more protein for fuel.
What are the long-term health risks associated with GSD III?
The primary long-term risks include the development of liver growths like adenomas or liver cancer, progressive muscle weakness that may become more prominent in adulthood, and thickening of the heart walls. Regular specialist visits and personalized nutrition plans are essential to managing these risks.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many GSD III patients do you currently treat, and what is your experience with the myopathic (muscle) symptoms of this condition?
  2. 2.Which specialists (dietitian, cardiologist, hepatologist) are part of your core team for coordinating my care?
  3. 3.What is your specific recommendation for liver imaging frequency for my (or my child's) age and current liver enzyme levels?
  4. 4.What level of Creatine Kinase (CK) should we consider 'concerning' for my specific situation?
  5. 5.Can you provide a clear, written plan for emergency care or illness if I am unable to maintain my normal dietary intake?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III.

    Hijazi G, Paschall A, Young SP, et al.

    Molecular genetics and metabolism reports 2021; (29()):100821 doi:10.1016/j.ymgmr.2021.100821.

    PMID: 34820282
  2. 2

    Avascular necrosis as an uncommon manifestation in glycogen storage disease type III: diagnostic and therapeutic challenges.

    Gorial FI, Awadh NI, Khunda SS, et al.

    Oxford medical case reports 2025; (2025(8)):omaf145 doi:10.1093/omcr/omaf145.

    PMID: 40843042
  3. 3

    Liver transplantation in glycogen storage disease type III: A case-series.

    Gay S, Bigot A, d'Alteroche L, et al.

    JIMD reports 2025; (66(1)):e12463 doi:10.1002/jmd2.12463.

    PMID: 39866164
  4. 4

    Glycogen storage disease type III: a mixed-methods study to assess the burden of disease.

    Evins A, Mayhew J, Cimms T, et al.

    Therapeutic advances in endocrinology and metabolism 2024; (15()):20420188231224233 doi:10.1177/20420188231224233.

    PMID: 38196773
  5. 5

    The biallelic novel pathogenic variants in AGL gene in a chinese patient with glycogen storage disease type III.

    Wang J, Yu Y, Cai C, et al.

    BMC pediatrics 2022; (22(1)):284 doi:10.1186/s12887-022-03252-y.

    PMID: 35578201
  6. 6

    Beneficial Effects of Modified Atkins Diet in Glycogen Storage Disease Type IIIa.

    Olgac A, İnci A, Okur İ, et al.

    Annals of nutrition & metabolism 2020; (76(4)):233-241 doi:10.1159/000509335.

    PMID: 32712609
  7. 7

    Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring.

    Halaby CA, Young SP, Austin S, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(12)):2686-2694 doi:10.1038/s41436-019-0561-7.

    PMID: 31263214
  8. 8

    Glycogen Storage Disease in Twins: When Two Lives Reflect One Silent Battle.

    Shah RK, Khan SA, Devkota D, et al.

    Clinical case reports 2026; (14(1)):e71889 doi:10.1002/ccr3.71889.

    PMID: 41567525
  9. 9

    Cardiovascular involvement in glycogen storage diseases.

    Pinós T, Cubbon RM, Santalla A, et al.

    Nature reviews. Cardiology 2026; (23(1)):39-59 doi:10.1038/s41569-025-01171-w.

    PMID: 40473899
  10. 10

    Muscle Ultrasound in Patients with Glycogen Storage Disease Types I and III.

    Verbeek RJ, Sentner CP, Smit GP, et al.

    Ultrasound in medicine & biology 2016; (42(1)):133-42.

    PMID: 26437929
  11. 11

    Glycogen Debrancher Enzyme Deficiency Myopathy.

    Sadeh M, Yosovich K, Dabby R

    Journal of clinical neuromuscular disease 2021; (22(4)):224-227 doi:10.1097/CND.0000000000000339.

    PMID: 34019008
  12. 12

    Hepatocellular Adenomas and Carcinoma in Asymptomatic, Non-Cirrhotic Type III Glycogen Storage Disease.

    Oterdoom LH, Verweij KE, Biermann K, et al.

    Journal of gastrointestinal and liver diseases : JGLD 2015; (24(4)):515-8 doi:10.15403/jgld.2014.1121.244.had.

    PMID: 26697579
  13. 13

    Data highlighting effects of Ketogenic diet on cardiomyopathy and hepatopathy in Glycogen storage disease Type IIIA.

    Marusic T, Zerjav Tansek M, Sirca Campa A, et al.

    Data in brief 2020; (32()):106205 doi:10.1016/j.dib.2020.106205.

    PMID: 32939375
  14. 14

    Liver transplantation in patients with type IIIa glycogen storage disease, cirrhosis and hepatocellular carcinoma.

    Iglesias Jorquera E, Tomás Pujante P, Ruiz García G, et al.

    Revista espanola de enfermedades digestivas 2019; (111(2)):168-169 doi:10.17235/reed.2018.5856/2018.

    PMID: 30318896
  15. 15

    Report of an Iranian child with chronic abdominal pain and constipation diagnosed as glycogen storage disease type IX: a case report.

    Zamanfar D, Hashemi-Soteh SM, Ghazaiean M, Keyhanian E

    Journal of medical case reports 2024; (18(1)):14 doi:10.1186/s13256-023-04295-0.

    PMID: 38212860
  16. 16

    Spectrum of AGL mutations in Chinese patients with glycogen storage disease type III: identification of 31 novel mutations.

    Lu C, Qiu Z, Sun M, et al.

    Journal of human genetics 2016; (61(7)):641-5 doi:10.1038/jhg.2016.24.

    PMID: 26984562
  17. 17

    Diurnal variability of glucose tetrasaccharide (Glc4) excretion in patients with glycogen storage disease type III.

    Young SP, Khan A, Stefanescu E, et al.

    JIMD reports 2021; (58(1)):37-43 doi:10.1002/jmd2.12181.

    PMID: 33728245
  18. 18

    Long-term personalized high-protein, high-fat diet in pediatric patients with glycogen storage disease type IIIa: Evaluation of myopathy, metabolic control, physical activity, growth, and dietary compliance.

    Kalkan Uçar S, Altınok YA, Mansuroglu Y, et al.

    Journal of inherited metabolic disease 2024; (47(5)):1001-1017 doi:10.1002/jimd.12741.

    PMID: 38623712

This page provides general information on building a care team and surveillance roadmap for GSD III. It is for educational purposes only and does not replace professional medical advice. Always consult your specialized healthcare team for personalized monitoring and treatment plans.

Get notified when new evidence is published on Glycogen storage disease due to glycogen debranching enzyme deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.